{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:02:01Z","timestamp":1790892121116,"version":"4.1.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.35353","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T16:31:02Z","timestamp":1637339462000},"page":"e2135353","source":"Crossref","is-referenced-by-count":43,"title":["Association of Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and Incidence of Gout in Taiwan"],"prefix":"10.1001","volume":"4","author":[{"given":"Mu-Chi","family":"Chung","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan"},{"name":"PhD Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan"},{"name":"Rong Hsing Research Center For Translational Medicine, National Chung Hsing University, Taichung, Taiwan"},{"name":"Department of Biotechnology, Asia University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peir-Haur","family":"Hung","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan"},{"name":"Department of Applied Life Science and Health, Chia-Nan University of Pharmacy and Science, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Jen","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Department of Urology, China Medical University and Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laing-You","family":"Wu","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hsiang","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Urology, China Medical University and Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Ju","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeng-Jer","family":"Shieh","sequence":"additional","affiliation":[{"name":"Rong Hsing Research Center For Translational Medicine, National Chung Hsing University, Taichung, Taiwan"},{"name":"Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan"},{"name":"Department of Education and Research, Taichung Veterans General Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Jung","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Public Health, College of Public Health, China Medical University, Taichung, Taiwan"},{"name":"Department of Medical Research, China Medical University Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,11,19]]},"reference":[{"key":"zoi210997r1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1159\/issn.0302-5144","article-title":"Time to target uric acid to retard chronic kidney disease progression.","volume":"192","author":"Uchida","year":"2018","journal-title":"Contrib Nephrol"},{"key":"zoi210997r2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2020.07.006","article-title":"Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease.","volume":"80","author":"Borghi","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"5","key":"zoi210997r3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s40265-019-01081-5","article-title":"Cardiovascular disease in gout and the protective effect of treatments including urate-lowering therapy.","volume":"79","author":"Gupta","year":"2019","journal-title":"Drugs"},{"issue":"7","key":"zoi210997r4","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/dom.v22.7","article-title":"Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: a subanalysis of EMPA-REG OUTCOME.","volume":"22","author":"Verma","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"zoi210997r5","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? insights from a mediation analysis of the EMPA-REG OUTCOME Trial.","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"issue":"4","key":"zoi210997r6","doi-asserted-by":"publisher","first-page":"700","DOI":"10.2215\/CJN.06080616","article-title":"SGLT2 inhibition in the diabetic kidney\u2014from mechanisms to clinical outcome.","volume":"12","author":"van Bommel","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"zoi210997r7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/bdd.v35.7","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.","volume":"35","author":"Chino","year":"2014","journal-title":"Biopharm Drug Dispos"},{"issue":"7","key":"zoi210997r8","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","article-title":"Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors.","volume":"16","author":"Dehlin","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"zoi210997r9","first-page":"157","article-title":"Accuracy of diabetes diagnosis in health insurance claims data in Taiwan.","volume":"104","author":"Lin","year":"2005","journal-title":"J Formos Med Assoc"},{"issue":"10","key":"zoi210997r10","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1002\/art.39254","article-title":"2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative.","volume":"67","author":"Neogi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"zoi210997r11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12891-015-0614-2","article-title":"Validity of gout diagnosis in Swedish primary and secondary care\u2014a validation study.","volume":"16","author":"Dehlin","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"issue":"3","key":"zoi210997r12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/acr.2019.71.issue-3","article-title":"Gout, hyperuricemia, and crystal-associated disease network consensus statement regarding labels and definitions for disease elements in gout.","volume":"71","author":"Bursill","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"zoi210997r13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.v10.2","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies.","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"issue":"10","key":"zoi210997r14","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/sim.6058","article-title":"Metrics for covariate balance in cohort studies of causal effects.","volume":"33","author":"Franklin","year":"2014","journal-title":"Stat Med"},{"issue":"22","key":"zoi210997r15","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi210997r16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","article-title":"Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.","volume":"156","author":"Wilding","year":"2012","journal-title":"Ann Intern Med"},{"issue":"9896","key":"zoi210997r17","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"zoi210997r18","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1136\/annrheumdis-2017-212288","article-title":"Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis.","volume":"77","author":"Dalbeth","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"zoi210997r19","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/15257770802136032","article-title":"Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy.","volume":"27","author":"Becker","year":"2008","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"1","key":"zoi210997r20","doi-asserted-by":"publisher","first-page":"F173","DOI":"10.1152\/ajprenal.00462.2018","article-title":"SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1.","volume":"316","author":"Novikov","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"zoi210997r21","doi-asserted-by":"publisher","first-page":"6791","DOI":"10.1038\/s41598-018-25054-y","article-title":"High basolateral glucose increases sodium-glucose cotransporter 2 and reduces sirtuin-1 in renal tubules through glucose transporter-2 detection.","volume":"8","author":"Umino","year":"2018","journal-title":"Sci Rep"},{"issue":"11","key":"zoi210997r22","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.cardfail.2020.08.015","article-title":"Uric acid is a biomarker of oxidative stress in the failing heart: lessons learned from trials with allopurinol and SGLT2 inhibitors.","volume":"26","author":"Packer","year":"2020","journal-title":"J Card Fail"},{"issue":"10055","key":"zoi210997r23","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","article-title":"Gout.","volume":"388","author":"Dalbeth","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"zoi210997r24","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease.","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"zoi210997r25","doi-asserted-by":"publisher","first-page":"186","DOI":"10.7326\/M19-2610","article-title":"Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study.","volume":"172","author":"Fralick","year":"2020","journal-title":"Ann Intern Med"},{"issue":"5","key":"zoi210997r26","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/dom.2018.20.issue-5","article-title":"Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: post-hoc analyses of four clinical trials.","volume":"20","author":"Tonneijck","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"zoi210997r27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2174\/1871530315666150324114149","article-title":"Beneficial effects of vildagliptin on metabolic parameters in patients with type 2 diabetes.","volume":"15","author":"Shimodaira","year":"2015","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"2","key":"zoi210997r28","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.ijcard.2014.07.023","article-title":"Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity.","volume":"176","author":"Yamagishi","year":"2014","journal-title":"Int J Cardiol"},{"issue":"2","key":"zoi210997r29","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/dom.2018.20.issue-2","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials.","volume":"20","author":"Zhao","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"zoi210997r30","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"issue":"10","key":"zoi210997r31","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/dom.2014.16.issue-10","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.","volume":"16","author":"Yale","year":"2014","journal-title":"Diabetes Obes Metab"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2786352\/chung_2021_oi_210997_1636652796.07805.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T16:31:08Z","timestamp":1637339468000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2786352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,19]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.35353","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,19]]}}}